Uterine Cervical Cancer Clinical Trial
Official title:
Phase I-II Study of Palliative Treatment With Nimotuzumab as a Second, Third Line or More of Treatment for Advanced or Metastatic Cervical Cancer
The following is an open label, non comparative, pilot study of palliative treatment as a
second, third line or more of treatment in patients with recurrent, persistent or Metastatic
Cervical Cancer; it has a limited sample of 15 patients with the primary goal of evaluating
the response (defined as: Complete, partial or stable disease) to treatment with a
Monoclonal Antibody, Nimotuzumab, on a weekly basis + CDDP 50mg/m2/BSA as a single agent
every 3 weeks for patients with good renal function (Creatinine clearance => 60) or
Gemcitabine 800 mg/m2/BSA in patients with renal failure (Creatinine clearance <60).
Secondary objectives consist of evaluating disease-free survival, overall survival and
assess patient tolerance to treatment with Nimotuzumab.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01234480 -
Intended Use Study of the BD SurePath Plus™ Pap
|
||
Completed |
NCT05022511 -
Three Birds With One Stone
|
N/A | |
Recruiting |
NCT04857528 -
Detecting HPV DNA in Anal and Cervical Cancers
|
||
Completed |
NCT01755897 -
A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients
|
N/A | |
Recruiting |
NCT01667211 -
Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01226264 -
Diffusion MRI; Predictive Value for Cervical Uterine Cancer Recurrence
|
N/A | |
Recruiting |
NCT03961191 -
DNA Methylation for Screening Uterine Cervical Lesions: A Case-control Study
|
||
Enrolling by invitation |
NCT01393470 -
Evaluation of Long-term HPV Vaccine Efficacy
|
N/A | |
Terminated |
NCT00421096 -
Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer
|
Phase 2 | |
Terminated |
NCT01284348 -
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT03961178 -
A Cohort Study for the Following up of Conization
|
||
Terminated |
NCT02317302 -
FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06254846 -
Evaluation of First-void Urine as an Alternative to Cervical Sampling for Human Papillomavirus (HPV) Testing in Cervical Cancer Screening (Single-center Study).
|
N/A | |
Not yet recruiting |
NCT05824494 -
Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors
|
Phase 2 | |
Completed |
NCT00184093 -
Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03960879 -
DNA Methylation for Screening Uterine Cervical Lesions
|
||
Recruiting |
NCT04886700 -
Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer
|
Phase 2 | |
Enrolling by invitation |
NCT05231993 -
Clinical Triage and Treatment of Atypical Glandular Cells (AGC) Detected in Screening
|
N/A | |
Recruiting |
NCT02036164 -
Adjuvant Chemotherapy for Locally Advanced Cervical Cancer
|
Phase 3 | |
Recruiting |
NCT04974424 -
Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV
|